Related Experiment Video
Updated: Jul 16, 2026
07:36
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy.
Hridesh Banerjee1, Onyedikachi V Onyekachi1, Hector Nieves-Rosado1
1University of Pittsburgh Pittsburgh, PA United States.
Cancer Immunology Research
|July 15, 2026
Summary
Targeting T cell Immunoglobulin and Mucin 3 (Tim-3) on regulatory T cells (Treg) enhances antitumor immunity. Inhibiting Tim-3 on tumor Treg reduces tumor burden and T-cell exhaustion without affecting immune tolerance.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Regulatory T cells (Treg) suppress antitumor immunity, posing a challenge for cancer therapies.
- Targeting Treg is a promising strategy, but maintaining general immune tolerance is difficult.
- Identifying specific markers on tumor-infiltrating Treg is crucial for developing effective cancer treatments.
Purpose of the Study:
- To investigate the role of T cell Immunoglobulin and Mucin 3 (Tim-3) in tumor-infiltrating Treg function and survival.
- To determine if targeting Tim-3 on Treg can enhance antitumor immunity without compromising peripheral immune tolerance.
- To explore Tim-3 as a therapeutic target for sensitizing tumors to immunotherapy.
Main Methods:
- Utilized genetic deletion of Tim-3 in regulatory T cells (Treg) in mouse models.
- Assessed tumor growth, T-cell exhaustion, and peripheral immune homeostasis.
- Investigated the combination of Tim-3 blockade with PD-1 checkpoint inhibitors.
- Analyzed Tim-3 expression in Treg from a human clinical trial cohort.
Main Results:
- Tim-3 expression on tumor Treg is essential for their function and survival, partly via Akt and FOXO1 signaling.
- Deleting Tim-3 in Treg delayed tumor-specific T-cell exhaustion and reduced tumor burden.
- Treg-specific Tim-3 deletion enhanced the efficacy of PD-1 checkpoint blockade in resistant tumors.
- Decreased Tim-3+ tumor Treg correlated with clinical response to PD-1/LAG-3 combination therapy.
Conclusions:
- Tim-3 is a critical regulator of tumor Treg function and survival.
- Targeting Tim-3 on Treg represents a viable strategy to enhance antitumor immunity.
- Tim-3 blockade, particularly in combination with other immunotherapies, holds promise for treating cancer.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...